Health Catalyst (HCAT) Stock Forecast & Price Target

$7.09 +0.12 (+1.72%)

(As of 12/20/2024 05:31 PM ET)

Health Catalyst - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
3

Buy
9

Based on 12 Wall Street analysts who have issued ratings for Health Catalyst in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 3 have given a hold rating, and 9 have given a buy rating for HCAT.

Consensus Price Target

$11.79
66.31% Upside

According to the 12 analysts' twelve-month price targets for Health Catalyst, the average price target is $11.79. The highest price target for HCAT is $16.00, while the lowest price target for HCAT is $9.00. The average price target represents a forecasted upside of 66.31% from the current price of $7.09.

Get the Latest News and Ratings for HCAT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Health Catalyst and its competitors.

HCAT Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.79	$11.71	$11.42	$13.27
Forecasted Upside	66.31% Upside	52.85% Upside	31.38% Upside	38.69% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

HCAT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCAT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Health Catalyst Stock vs. The Competition

Type	Health Catalyst	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	66.31% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent HCAT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/26/2024	Piper Sandler 2 of 5 stars	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $12.00	+40.85%
11/14/2024	Stephens 4 of 5 stars	Boost Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00	+3.93%
11/13/2024	Citigroup 3 of 5 stars	Boost Target	Buy ➝ Buy	$9.00 ➝ $10.50	+18.78%
11/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$8.00 ➝ $9.00	+3.33%
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$8.00 ➝ $10.00	+24.84%
10/4/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $16.00	+109.70%
Get the Latest News and Ratings for HCAT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Health Catalyst and its competitors with MarketBeat's FREE daily newsletter.
9/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$10.00 ➝ $13.00	+72.41%
5/21/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00	+62.96%
5/10/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$14.00 ➝ $13.00	+104.72%
4/10/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Sector Weight
1/26/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00	+40.85%
1/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$14.00	+53.51%
11/1/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$15.00 ➝ $12.00	+65.52%
5/10/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:50 PM ET.

HCAT Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Health Catalyst is $11.79, with a high forecast of $16.00 and a low forecast of $9.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HCAT shares.
: According to analysts, Health Catalyst's stock has a predicted upside of 66.31% based on their 12-month stock forecasts.
: Health Catalyst has been rated by research analysts at Cantor Fitzgerald, Citigroup, Evercore ISI, Piper Sandler, Royal Bank of Canada, and Stephens in the past 90 days.
: Analysts like Health Catalyst less than other "medical" companies. The consensus rating score for Health Catalyst is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how HCAT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

This page (NASDAQ:HCAT) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Catalyst (HCAT) Stock Forecast & Price Target